title: The NIAID Radiation Countermeasures Program business model.
abstract: The National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures Development Program has developed an integrated approach to providing the resources and expertise required for the research, discovery, and development of radiation/nuclear medical countermeasures (MCMs). These resources and services lower the opportunity costs and reduce the barriers to entry for companies interested in working in this area and accelerate translational progress by providing goal-oriented stewardship of promising projects. In many ways, the radiation countermeasures program functions as a "virtual pharmaceutical firm," coordinating the early and mid-stage development of a wide array of radiation/nuclear MCMs. This commentary describes the radiation countermeasures program and discusses a novel business model that has facilitated product development partnerships between the federal government and academic investigators and biopharmaceutical companies.
authors.affiliation: Radiation/Nuclear Medical Countermeasures Development Program, National Institute for Allergy and Infectious Diseases (NIAID)/NIH, 6610 Rockledge Drive, Bethesda, MD 20892, USA.
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Hafer
authors.forename: Bert W
authors.initials: BW
authors.lastname: Maidment
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Hatchett
mesh_terms: D055808:Drug Discovery / Q000458:organization & administration*; D006801:Humans; D017146:Models, Organizational; D054579:National Institute of Allergy and Infectious Diseases (U.S.); D055818:Public-Private Sector Partnerships / Q000458:organization & administration*; D011832:Radiation Injuries / Q000188:drug therapy / Q000517:prevention & control*; D018788:Radioactive Hazard Release; D012109:Research Support as Topic / Q000458:organization & administration*; D014481:United States